CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	26.85	28.54	33.88	43.11	30.17	15.14
Revenue Growth (YoY)	21.72%	-15.77%	-21.41%	42.89%	99.25%	266.52%
Cost of Revenue	17.24	17.39	13.83	15.83	12.56	9.51
Gross Profit	9.61	11.15	20.05	27.28	17.61	5.63
Selling, General & Admin	44.42	41.44	41.84	37.78	38.41	27.48
Research & Development	8.74	8.92	9.86	16	14.42	11.47
Other Operating Expenses	-0	-0	-6.37	-	-	-
Operating Expenses	53.16	50.36	45.33	53.77	52.83	38.95
Operating Income	-43.55	-39.21	-25.28	-26.49	-35.22	-33.31
Interest Expense	-0.92	-0.87	-0.02	-0.06	-	-0
Interest & Investment Income	0.26	0.54	0.63	0.19	0.32	0.87
Earnings From Equity Investments	-2.25	-1.19	-0.05	-0.85	-	-
Currency Exchange Gain (Loss)	-0.84	-0.19	0.2	3.24	0.32	-1.26
Other Non Operating Income (Expenses)	0.05	0.19	0.76	0.04	0.09	0.08
EBT Excluding Unusual Items	-47.24	-40.74	-23.75	-23.93	-34.49	-33.62
Gain (Loss) on Sale of Investments	-1.42	1.7	-2.59	-3.57	4.8	4.32
Gain (Loss) on Sale of Assets	-0.02	0.48	-	-2.06	-0.07	1.15
Asset Writedown	-0.7	-0.7	-	-8.72	-	-1.54
Other Unusual Items	-	-	-	-	0.47	-
Pretax Income	-49.39	-39.26	-26.34	-38.28	-35.84	-47.51
Income Tax Expense	-	-	-0.08	1.98	-	-
Earnings From Continuing Operations	-49.39	-39.26	-26.26	-40.26	-35.84	-47.51
Minority Interest in Earnings	-	-	-0.68	-0.76	-0.81	-0.78
Net Income	-49.39	-39.26	-26.94	-41.01	-36.65	-48.29
Preferred Dividends & Other Adjustments	-	-	0.02	-	-	-
Net Income to Common	-49.39	-39.26	-26.96	-41.01	-36.65	-48.29
Shares Outstanding (Basic)	17	15	13	14	14	11
Shares Outstanding (Diluted)	17	15	13	14	14	11
Shares Change (YoY)	19.10%	14.82%	-2.10%	0.27%	23.23%	15.12%
EPS (Basic)	-2.98	-2.56	-2.02	-3.01	-2.69	-4.37
EPS (Diluted)	-2.98	-2.56	-2.02	-3.01	-2.69	-4.37
Free Cash Flow	-	-29.45	-20.17	-26.7	-35.79	-27.39
Free Cash Flow Per Share	-	-1.92	-1.51	-1.96	-2.63	-2.48
Gross Margin	35.80%	39.06%	59.19%	63.28%	58.38%	37.20%
Operating Margin	-162.21%	-137.41%	-74.62%	-61.45%	-116.74%	-220.02%
Profit Margin	-183.96%	-137.57%	-79.58%	-95.14%	-121.50%	-318.92%
Free Cash Flow Margin	-	-103.19%	-59.54%	-61.94%	-118.63%	-180.87%
EBITDA	-42.27	-36.88	-21.54	-24.07	-33.4	-31.35
EBITDA Margin	-157.46%	-129.24%	-63.58%	-55.84%	-110.72%	-207.08%
D&A For EBITDA	1.27	2.33	3.74	2.42	1.82	1.96
EBIT	-43.55	-39.21	-25.28	-26.49	-35.22	-33.31
EBIT Margin	-162.21%	-137.41%	-74.62%	-61.45%	-116.74%	-220.02%
Revenue as Reported	28.54	28.54	33.88	43.11	30.17	15.14

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q